TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Arm Label: Restrictive Red blood cell Transfusion; Type: EXPERIMENTAL; Interventions: Other: Red blood cell Transfusion | Arm Label: Liberal Red blood Cell Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell Transfusion | Intervention Type: OTHER; Name: Red blood cell Transfusion; Assigned to Arm(s): Liberal Red blood Cell Transfusion, Restrictive Red blood cell Transfusion
B: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
C: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Arm Label: Restrictive; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion | Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Procedure: Blood Transfusion | Intervention Type: PROCEDURE; Name: Blood Transfusion; Assigned to Arm(s): Liberal, Restrictive
B: Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Procedure: Restrictive transfusion, Biological: red blood transfusion | Arm Label: Liberal transfusion strategy; Type: EXPERIMENTAL; Interventions: Procedure: Liberal transfusion, Biological: red blood transfusion | Intervention Type: PROCEDURE; Name: Restrictive transfusion; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: PROCEDURE; Name: Liberal transfusion; Assigned to Arm(s): Liberal transfusion strategy | Intervention Type: BIOLOGICAL; Name: red blood transfusion; Assigned to Arm(s): Liberal transfusion strategy, Restrictive transfusion strategy
C: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
D: Arm Label: Restrictive transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal transfusion strategy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myocardial Ischemia and Transfusion Pilot
Brief Summary: The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome.


Options:
A: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
B: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
C: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
D: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake
Brief Summary: The overall goals of this study are to (1) expand knowledge about interactions of levetiracetam with alcohol by assessing the effects of levetiracetam compared to placebo in moderate and heavy social alcohol users and (2) to test the AccuswayTM platform as a tool to measure postural control (which has been used as a marker of intoxication) and the effects of levetiracetam on postural control.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone plus Gabapentin | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Other: Inactive Placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Naltrexone plus Gabapentin; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Inactive Placebo; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: naltrexone (Revia); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: acamprosate (Campral); Assigned to Arm(s): N/A
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam (Keppra), Drug: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam (Keppra), Drug: Placebo | Intervention Type: DRUG; Name: Levetiracetam (Keppra); Assigned to Arm(s): Group A, Group B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A, Group B
D: Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia
Brief Summary: Study to evaluate the safety and efficacy of oral CEM-101 compared to oral Levofloxacin in the treatment of adults with moderate to moderately severe community-acquired bacterial pneumonia.


Options:
A: Arm Label: Ceftaroline fosamil for injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ceftriaxone, Drug: Placebo | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for injection | Intervention Type: DRUG; Name: Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone
B: Arm Label: Levofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levofloxacin | Arm Label: CEM-101; Type: EXPERIMENTAL; Interventions: Drug: CEM-101 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): Levofloxacin | Intervention Type: DRUG; Name: CEM-101; Assigned to Arm(s): CEM-101
C: Arm Label: Rapid result; Type: EXPERIMENTAL; Interventions: Procedure: Access to diagnostic test | Arm Label: Delayed result; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Access to diagnostic test; Assigned to Arm(s): Rapid result
D: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: Ceftaroline fosamil for Injection, Drug: Clarithromycin | Arm Label: IV Ceftriaxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Ceftriaxone, Drug: Placebo, Drug: Clarithromycin | Intervention Type: DRUG; Name: Ceftaroline fosamil for Injection; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: IV Ceftriaxone; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV Ceftriaxone | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Ceftaroline fosamil for Injection, IV Ceftriaxone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
Brief Summary: This study, supported by Charley's Fund, Inc., is being done to determine if the drug Revatio®(also known as Sildenafil), as compared to placebo (an inactive substance that looks like the study drug, but contains no medication), improves heart function in people with Duchenne Muscular Dystrophy and Becker Muscular Dystrophy (DBMD).

In people with DBMD, dystrophin is not present or lacking in heart and muscle. This is associated with abnormalities in an enzyme called "neuronal nitric oxide synthase" or nNOS, and leads to decreases in "cyclic GMP," which is necessary for proper function of those muscles. Revatio blocks an enzyme called phosphodiesterase 5 (PDE5), and helps to restore the normal amounts of cyclic GMP. The purpose of this research is to determine if Revatio is safe for people with DBMD and if it can improve heart function.

Hypothesis : PDE5 inhibition, with the use of Revatio, will improve cardiac function in patients with DBMD.


Options:
A: Arm Label: Revatio (sildenafil); Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: OTHER; Interventions: Drug: Sildenafil | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Placebo, Revatio (sildenafil)
B: Arm Label: Continuous regimen; 6mg/kg once weekly; Type: EXPERIMENTAL; Interventions: Drug: GSK2402968, Drug: matched placebo | Arm Label: Intermittent regimen; 6mg/kg twice weekly; Type: EXPERIMENTAL; Interventions: Drug: GSK2402968, Drug: matched placebo | Intervention Type: DRUG; Name: GSK2402968; Assigned to Arm(s): Continuous regimen; 6mg/kg once weekly, Intermittent regimen; 6mg/kg twice weekly | Intervention Type: DRUG; Name: matched placebo; Assigned to Arm(s): Continuous regimen; 6mg/kg once weekly, Intermittent regimen; 6mg/kg twice weekly
C: Arm Label: Implantable Counterpulsation Therapy; Type: EXPERIMENTAL; Interventions: Device: C-Pulse™ (Implantable Counterpulsation Therapy) | Intervention Type: DEVICE; Name: C-Pulse™ (Implantable Counterpulsation Therapy); Assigned to Arm(s): Implantable Counterpulsation Therapy
D: Arm Label: eplerenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: eplerenone | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): eplerenone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): sugar pill

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AMES + Brain Stimulation: Treatment for Profound Plegia in Stroke
Brief Summary: The procedure involves: (1) assisted hand movement by a mechanical device, (2) mechanical vibration applied to the surface of the forearm, and (3) stimulation of the brain with either transcranial magnetic stimulation (TMS) or transcortical direct current stimulation (DCS). These 3 components of the procedure are carried out simultaneously. Each subject will be evaluated pre- and post-treatment with several clinical tests of functional movement. The hypotheses of this project are that the AMES+rTMS and AMES+tDCS procedures are safe and will enable most of the stroke patients to recover finger extension.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HEP-OKS; Type: EXPERIMENTAL; Interventions: Behavioral: hemifield eye patching (HEP) + optokinetic stimulation (OKS) | Intervention Type: BEHAVIORAL; Name: hemifield eye patching (HEP) + optokinetic stimulation (OKS); Assigned to Arm(s): HEP-OKS
B: Arm Label: Mirror therapy; Type: EXPERIMENTAL; Interventions: Other: Mirror therapy | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Mirror therapy; Assigned to Arm(s): Mirror therapy | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
C: Arm Label: 1 tDCS-Sham; Type: EXPERIMENTAL; Interventions: Procedure: transcranial direct current stimulation (tDCS) | Arm Label: 2 Sham-tDCS; Type: EXPERIMENTAL; Interventions: Procedure: Sham stimulation, then tDCS | Arm Label: 3 Sham-Sham; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham stimulation | Intervention Type: PROCEDURE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): 1 tDCS-Sham | Intervention Type: PROCEDURE; Name: Sham stimulation, then tDCS; Assigned to Arm(s): 2 Sham-tDCS | Intervention Type: PROCEDURE; Name: Sham stimulation; Assigned to Arm(s): 3 Sham-Sham
D: Arm Label: AMES therapy with rTMS; Type: ACTIVE_COMPARATOR; Interventions: Device: AMES + brain stimulation | Arm Label: AMES therapy with tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: AMES + brain stimulation | Intervention Type: DEVICE; Name: AMES + brain stimulation; Assigned to Arm(s): AMES therapy with rTMS, AMES therapy with tDCS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D and Omega-3 Trial (VITAL)
Brief Summary: The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The 5-year intervention phase (study pill-taking, median 5.3 years) has ended; post-intervention observational follow-up of study participants is ongoing.


Options:
A: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
B: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D and Omega-3 Trial (VITAL)
Brief Summary: The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The 5-year intervention phase (study pill-taking, median 5.3 years) has ended; post-intervention observational follow-up of study participants is ongoing.


Options:
A: Arm Label: Vitamin D + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Drug: omega-3 fatty acids (fish oil) | Arm Label: Vitamin D + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: omega-3 fatty acids (fish oil), Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin D3; Assigned to Arm(s): Vitamin D + fish oil, Vitamin D + fish oil placebo | Intervention Type: DRUG; Name: omega-3 fatty acids (fish oil); Assigned to Arm(s): Vitamin D + fish oil, Vitamin D placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D placebo + fish oil, Vitamin D placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D + fish oil placebo, Vitamin D placebo + fish oil placebo
B: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: OMEGA-3; Type: ACTIVE_COMPARATOR; Interventions: Drug: OMEGA-3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo soybean oil | Intervention Type: DRUG; Name: OMEGA-3; Assigned to Arm(s): OMEGA-3 | Intervention Type: DRUG; Name: Placebo soybean oil; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing The Effect Of Educational Intervention Based On Supportive Behaviour Leadership Model On Head Nurses' Performance In TUMS Hospitals: RCT In 2010
Brief Summary: Hypothesis Applying Educational Intervention Based On Supportive behaviour Leadership Model has positive effect on Head Nurses' performance in TUMS Hospitals.

Specific objectives

1. Assessing the impact of supportive leadership behaviour on individual head nurse
2. Assessing the impact of supportive leadership behaviour on nursing team
3. Assessing the impact of supportive leadership behaviour on TUMS organizational success, especially in cross-functional environments
4. Develop a specific plan for effectively supportive leadership behaviour the efforts of others to sustain and encourage productive performance and employee satisfaction


Options:
A: Arm Label: Retreat; Type: EXPERIMENTAL; Interventions: Other: Retreat | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Retreat; Assigned to Arm(s): Retreat
B: Arm Label: Educational Intervention; Type: EXPERIMENTAL; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance | Intervention Type: OTHER; Name: Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance; Assigned to Arm(s): CONTROL, Educational Intervention
C: Arm Label: Tele-intensivist consultation; Type: EXPERIMENTAL; Interventions: Other: Tele-intensivist consultation | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Simulated "observation" by ICU physician | Intervention Type: OTHER; Name: Tele-intensivist consultation; Assigned to Arm(s): Tele-intensivist consultation | Intervention Type: OTHER; Name: Simulated "observation" by ICU physician; Assigned to Arm(s): Control
D: Intervention Type: BEHAVIORAL; Name: Leadership development program educational intervention; Assigned to Arm(s): N/A

Answer: B